Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
Cutaneous T-cell lymphoma/mycosis fungoides (CTCL/MF) is a rare lymphoproliferative disorder which can present as an indolent or as an aggressive process involving skin, lymph nodes, and blood. In stages IA, IB and IIA, it is usually managed with topical medications and phototherapy. If there is pro...
Main Authors: | Kaminetzky, David, Hymes, Kenneth B |
---|---|
Format: | Online |
Language: | English |
Published: |
Dove Medical Press
2008
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727893/ |
Similar Items
-
Advanced-Stage Primary Cutaneous T-Cell Lymphoma Treated with Bexarotene and Denileukin Diftitox
by: Cervigón-González, Iván, et al.
Published: (2011) -
Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma
by: Ansell, Stephen M., et al.
Published: (2011) -
Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission
by: Fuentes, Alejandra C., et al.
Published: (2015) -
Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome
by: Prince, H. Miles, et al.
Published: (2013) -
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma
by: Telang, Sucheta, et al.
Published: (2011)